Company News: GlaxoSmithKline and Nabi

Share this article:
GlaxoSmithKline acquired exclusive worldwide rights to in-license a nicotine-addiction vaccine developed by Nabi and to use the biotech firm's technology to develop its own vaccines. GSK will pay Nabi a $40-million upfront for the option of in-licensing NicVAX following completion of phase III testing. Nabi can receive as much as $500 million in option fees and regulatory, development and sales milestones for NicVAX, as well as from any second-generation GSK nicotine vaccines. Should GSK exercise its option, Nabi is also entitled to receive double-digit royalties on global sales of NicVAX and any follow-on products. The deal is expected to close in first quarter 2010.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions